AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10194091 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate, 300 mg i.m. every 3 weeks for 6 months
Number of subjects: 51
Study 10194091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 10194091 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration for 1 year
Number of subjects: 51
Study 7761078 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (7.5‐10 mg weekly)
Number of subjects: 13
Study 7761078 — intervention group
Group type: COMPARATOR
Intervention: Other therapies (im. gold 50 mg weekly or per os steroid max. 10 mg daily)
Number of subjects: 13
Study 2183079 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (TP5)
Number of subjects: 108
Study 2183079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 2183079 — intervention group
Group type: COMPARATOR
Intervention: Control group (young healthy adults)
Number of subjects: 108
Study 7286051 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg
Number of subjects: 134
Study 7286051 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50 mg
Number of subjects: 134
Study 7286051 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 75 mg
Number of subjects: 134
Study 7286051 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 100 mg
Number of subjects: 134
Study 31088512 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (NIRS) measuring cerebral oxygen saturation (rSO2)
Number of subjects: 118
Study 27892891 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg loading dose within 18 hours before surgery, followed by 40 mg maintenance dose starting at least 12 hours after surgery for 7 days)
Number of subjects: 648
Study 27892891 — intervention group
Group type: COMPARATOR
Intervention: Placebo (80 mg loading dose within 18 hours before surgery, followed by placebo maintenance dose)
Number of subjects: 648
Study 27892891 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 648
Study 27892891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 648
Study 26483221 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 30
Study 26483221 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 23554155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 50
Study 23554155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21245790 — intervention group
Group type: COMPARATOR
Intervention: Sham spinal manipulation therapy (12 treatments over 1 month)
Number of subjects: 60
Study 21245790 — intervention group
Group type: COMPARATOR
Intervention: Spinal manipulation therapy (12 treatments over 1 month, no maintenance)
Number of subjects: 60
Study 21245790 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation therapy with maintenance (12 treatments over 1 month, maintenance every 2 weeks for 9 months)
Number of subjects: 60
Study 19563364 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 208
Study 19563364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 17192450 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory abdominal CT imaging
Number of subjects: 152
Study 17192450 — intervention group
Group type: COMPARATOR
Intervention: Selective abdominal CT imaging
Number of subjects: 152
Study 15036568 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5% twice daily
Number of subjects: 20
Study 15036568 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 0.5% twice daily
Number of subjects: 20
Study 15036568 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 20
Study 11427783 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (light, moderate, vigorous intensity)
Number of subjects: 0
Study 11427783 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training and aerobic exercise
Number of subjects: 0
Study 11427783 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise dose
Number of subjects: 0
Study 9931794 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation (within 6 h postoperatively) after transmediastinal esophagectomy
Number of subjects: 235
Study 9931794 — intervention group
Group type: COMPARATOR
Intervention: Prolonged ventilation (> 24 h) after transmediastinal esophagectomy
Number of subjects: 235
Study 9931794 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation (within 6 h postoperatively) after transthoracic esophagectomy
Number of subjects: 235
Study 9931794 — intervention group
Group type: COMPARATOR
Intervention: Prolonged ventilation (> 24 h) after transthoracic esophagectomy
Number of subjects: 235
Study 8183099 — intervention group
Group type: EXPERIMENTAL
Intervention: 15N-alanine infusion
Number of subjects: 5
Study 3369320 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up interviews
Number of subjects: 0
Study 3369320 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring procedures
Number of subjects: 0
Study 3369320 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30954200 — intervention group
Group type: EXPERIMENTAL
Intervention: Unna's boot (compression therapy)
Number of subjects: 15
Study 30954200 — intervention group
Group type: COMPARATOR
Intervention: Noncompression therapy (conventional dressing)
Number of subjects: 15
Study 28822300 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000ml of mineral water within 10min
Number of subjects: 23
Study 28822300 — intervention group
Group type: COMPARATOR
Intervention: Control group (no water intake)
Number of subjects: 23
Study 25990361 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenems
Number of subjects: 79
Study 25990361 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 79
Study 23299526 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 831
Study 21067945 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 110
Study 21067945 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 110
Study 18201859 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative information
Number of subjects: 353
Study 18201859 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic information
Number of subjects: 353
Study 16836503 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg low dose test (LDT)
Number of subjects: 33
Study 16836503 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg standard dose test (SDT)
Number of subjects: 33
Study 16836503 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (C)
Number of subjects: 33
Study 12617260 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Number of subjects: 137
Study 10823311 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (3 g/d) and Vitamin E (1500 IU/d) for 8 days
Number of subjects: 9
Study 10823311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8900501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (TA) 4.2 +/- 0.5 mg/kg orally in a single dose
Number of subjects: 55
Study 8900501 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 55
Study 8900501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (TA)
Number of subjects: 55
Study 1710489 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin/bleomycin/vinblastine/dacarbazine) as salvage treatment
Number of subjects: 0
Study 1710489 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD combined with irradiation or cyclically alternated with MOPP (mechlorethamine/vincristine/procarbazine/prednisone)
Number of subjects: 0
Study 1710489 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based combinations
Number of subjects: 0
Study 6512981 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin (FOM) administered orally at doses of 50 to 100 mg/kg/day for children and 3 g/day for adults for 5 days.
Number of subjects: 47
Study 6512981 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin (FOM) treatment.
Number of subjects: 47
Study 30978117 — intervention group
Group type: EXPERIMENTAL
Intervention: HMOX1 rs2071746 polymorphism in PE patients
Number of subjects: 1235
Study 30978117 — intervention group
Group type: COMPARATOR
Intervention: Control group (1720 healthy women)
Number of subjects: 1235
Study 31630278 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomic profiling of plasma samples using proton nuclear magnetic resonance spectroscopy (1H NMR)
Number of subjects: 128
Study 31630278 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-metabolite model (lactate and acetate)
Number of subjects: 128
Study 31630278 — intervention group
Group type: EXPERIMENTAL
Intervention: Second metabolite model (D-glucose, pyruvate, acetoacetate)
Number of subjects: 128
Study 26683409 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave disinfection once a week for 4 weeks
Number of subjects: 40
Study 26683409 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave disinfection three times a week for 4 weeks
Number of subjects: 40
Study 26683409 — intervention group
Group type: COMPARATOR
Intervention: Baseline (control group)
Number of subjects: 40
Study 26197776 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron
Number of subjects: 38
Study 26197776 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 38
Study 26197776 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT₃ receptor antagonist with dexamethasone and aprepitant
Number of subjects: 38
Study 26197776 — intervention group
Group type: COMPARATOR
Intervention: 5‐HT₃ receptor antagonist with dexamethasone
Number of subjects: 38
Study 24724983 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 μg misoprostol sublingually and 20 IU oxytocin intravenously
Number of subjects: 120
Study 24724983 — intervention group
Group type: COMPARATOR
Intervention: 20 IU of intravenous oxytocin alone
Number of subjects: 120
Study 22968678 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily
Number of subjects: 350
Study 22968678 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 350
Study 19640954 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation with Bifidobacterium lactis and resistant starch
Number of subjects: 20
Study 19640954 — intervention group
Group type: COMPARATOR
Intervention: Prebiotic intervention
Number of subjects: 20
Study 19640954 — intervention group
Group type: COMPARATOR
Intervention: Probiotic intervention
Number of subjects: 20
Study 19640954 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 20
Study 17466857 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentacam measurements of central corneal thickness (CCT)
Number of subjects: 76
Study 17466857 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentacam measurements of peripheral corneal thickness
Number of subjects: 76
Study 17466857 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability of consecutive measurements
Number of subjects: 76
Study 17466857 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between age and corneal thickness
Number of subjects: 76
Study 17466857 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliability of pachymetry measurements
Number of subjects: 76
Study 15229756 — intervention group
Group type: EXPERIMENTAL
Intervention: American patients (higher invasive care)
Number of subjects: 1512
Study 15229756 — intervention group
Group type: COMPARATOR
Intervention: Canadian patients (more conservative care)
Number of subjects: 1512
Study 15229756 — intervention group
Group type: EXPERIMENTAL
Intervention: Both cohorts
Number of subjects: 1512
Study 11262775 — intervention group
Group type: EXPERIMENTAL
Intervention: Total joint arthroplasty (TJA)
Number of subjects: 48
Study 11262775 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 48
Study 9731852 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 intracervical gel (Prepidil)
Number of subjects: 90
Study 9731852 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 90
Study 7994450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment aiming at a blood pressure < or = 80 mmHg diastolic (group A)
Number of subjects: 2127
Study 7994450 — intervention group
Group type: COMPARATOR
Intervention: Unchanged therapy (group B)
Number of subjects: 2127
Study 7994450 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment (group A)
Number of subjects: 2127
Study 2481558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavitary bleomycin
Number of subjects: 22
Study 2481558 — intervention group
Group type: COMPARATOR
Intervention: Intracavitary talc
Number of subjects: 22
Study 1161965 — intervention group
Group type: EXPERIMENTAL
Intervention: clomipramine
Number of subjects: 0
Study 1161965 — intervention group
Group type: EXPERIMENTAL
Intervention: clomipramine and tryptophan
Number of subjects: 0
Study 1161965 — intervention group
Group type: EXPERIMENTAL
Intervention: desipramine and clomipramine
Number of subjects: 0
Study 1161965 — intervention group
Group type: EXPERIMENTAL
Intervention: desipramine and tryptophan
Number of subjects: 0
Study 31030233 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective course on 3D reconstruction and printing
Number of subjects: 30
Study 28597103 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (STR)
Number of subjects: 33
Study 28597103 — intervention group
Group type: EXPERIMENTAL
Intervention: Ski-ergometer training (ERG)
Number of subjects: 33
Study 25012806 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical 30 mL Foley balloon (FB)
Number of subjects: 199
Study 25012806 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical 60 mL Foley balloon (FB)
Number of subjects: 199
Study 25012806 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical 30 mL or 60 mL Foley balloon (FB)
Number of subjects: 199
Study 23589387 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol lozenges
Number of subjects: 620
Study 23589387 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 620
Study 21996929 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational inhalation exposure to carbon black (CB)
Number of subjects: 72
Study 21996929 — intervention group
Group type: COMPARATOR
Intervention: Healthy unexposed male office workers (referent group)
Number of subjects: 72
Study 18262711 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position (group A)
Number of subjects: 75
Study 18262711 — intervention group
Group type: COMPARATOR
Intervention: Prone position (group B)
Number of subjects: 75
Study 16840744 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3 or 5 mg/kg)
Number of subjects: 138
Study 16840744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 15115092 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV exposure category (homosexual/bisexual contact)
Number of subjects: 600
Study 15115092 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell counts of 200-500/mm3
Number of subjects: 600
Study 15115092 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 cell counts above 500/mm3
Number of subjects: 600
Study 15115092 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall PPD positivity
Number of subjects: 600
Study 11021769 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivagabine (1800 mg/day for 7 days)
Number of subjects: 0
Study 11021769 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9167761 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide at a dose of 50 mg/d
Number of subjects: 29
Study 9167761 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide at a dose of 50 mg/d with G-CSF
Number of subjects: 29
Study 8490006 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (165 mg Ca as CaCl2) added to a hamburger meal
Number of subjects: 0
Study 8490006 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (165 mg Ca as CaCl2) added to a wheat roll
Number of subjects: 0
Study 8490006 — intervention group
Group type: COMPARATOR
Intervention: Control studies to ensure haem-Fe degradation
Number of subjects: 0
Study 3026552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovolactovegetarian diet
Number of subjects: 58
Study 3026552 — intervention group
Group type: COMPARATOR
Intervention: Typical omnivorous diet
Number of subjects: 58
Study 31079087 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-guided balancing
Number of subjects: 222
Study 31079087 — intervention group
Group type: COMPARATOR
Intervention: Manual balancing
Number of subjects: 222
Study 29696918 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with diane‐35
Number of subjects: 60
Study 29696918 — intervention group
Group type: COMPARATOR
Intervention: diane‐35 alone
Number of subjects: 60
Study 26786573 — intervention group
Group type: EXPERIMENTAL
Intervention: 30,000 IU vitamin D3 once weekly for 8 weeks
Number of subjects: 44
Study 26786573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 24874782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive community-based group intervention focusing on diet, physical activity, and peer support
Number of subjects: 61
Study 24874782 — intervention group
Group type: COMPARATOR
Intervention: Control group (two 3-hour group sessions of diabetes self-management education)
Number of subjects: 61
Study 22698027 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized lifestyle counseling delivered primarily via telephone
Number of subjects: 230
Study 22698027 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 230
Study 19439067 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.2 pmol/kg/min)
Number of subjects: 7
Study 17879948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal IM862 daily for 6 months or until disease progression.
Number of subjects: 71
Study 17879948 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 6 months or until disease progression.
Number of subjects: 71
Study 15994014 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal compression (15 mmHg)
Number of subjects: 60
Study 15994014 — intervention group
Group type: COMPARATOR
Intervention: Low compression (10 mmHg)
Number of subjects: 60
Study 15994014 — intervention group
Group type: EXPERIMENTAL
Intervention: Both compression levels
Number of subjects: 60
Study 11944005 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial submissions approved for recording (75%)
Number of subjects: 5010
Study 11944005 — intervention group
Group type: EXPERIMENTAL
Intervention: Final score after resubmissions
Number of subjects: 5010
Study 11944005 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial score of sites approved after 3 or more submissions
Number of subjects: 5010
Study 11944005 — intervention group
Group type: EXPERIMENTAL
Intervention: Accuracy for left ventricular internal end-diastolic diameter (LVIDd)
Number of subjects: 5010
Study 11944005 — intervention group
Group type: EXPERIMENTAL
Intervention: Accuracy for ejection fraction (EF)
Number of subjects: 5010
Study 11944005 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproducibility for LVIDd
Number of subjects: 5010
Study 11944005 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproducibility for EF
Number of subjects: 5010
Study 11944005 — intervention group
Group type: EXPERIMENTAL
Intervention: Recording scores at baseline, 4, 12, and 18 months
Number of subjects: 5010
Study 11944005 — intervention group
Group type: EXPERIMENTAL
Intervention: Power analysis for LVIDd
Number of subjects: 5010
Study 11944005 — intervention group
Group type: EXPERIMENTAL
Intervention: Power analysis for EF
Number of subjects: 5010
Study 9819037 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of recombinant activated factor VII (rFVIIa) targeting a factor VII level of 10 IU/ml
Number of subjects: 26
Study 9819037 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of recombinant activated factor VII (rFVIIa)
Number of subjects: 26
Study 9819037 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel infusion of heparin, saline or dextrose‐saline
Number of subjects: 26
Study 7860545 — intervention group
Group type: COMPARATOR
Intervention: Thrombotic Stroke (TS)
Number of subjects: 50
Study 7860545 — intervention group
Group type: COMPARATOR
Intervention: Haemorrhagic Stroke (HS)
Number of subjects: 50
Study 2521435 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 5 micrograms/kg
Number of subjects: 80
Study 2521435 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 7 micrograms/kg
Number of subjects: 80
Study 2521435 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 10 micrograms/kg
Number of subjects: 80
Study 2521435 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 13 micrograms/kg
Number of subjects: 80
Study 2521435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.5 micrograms/kg
Number of subjects: 80
Study 2521435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.7 micrograms/kg
Number of subjects: 80
Study 2521435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 1.0 micrograms/kg
Number of subjects: 80
Study 2521435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 1.3 micrograms/kg
Number of subjects: 80
Study 1111368 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-nitrous oxide anesthesia (2 mg/kg morphine and 70% nitrous oxide in oxygen)
Number of subjects: 5
Study 1111368 — intervention group
Group type: COMPARATOR
Intervention: Control (normal mean arterial blood pressure)
Number of subjects: 5
Study 31775404 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium (PS) 40 mg administered 30 minutes before incision, 12 hours after THA, and every 12 hours for 2 days postoperatively
Number of subjects: 141
Study 31775404 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (Control)
Number of subjects: 141
Study 26231663 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65g/kg alcohol
Number of subjects: 0